1. Home
  2. TKC vs GRFS Comparison

TKC vs GRFS Comparison

Compare TKC & GRFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Turkcell Iletisim Hizmetleri AS

TKC

Turkcell Iletisim Hizmetleri AS

N/A

Current Price

$6.16

Market Cap

5.2B

ML Signal

N/A

Logo Grifols S.A.

GRFS

Grifols S.A.

N/A

Current Price

$8.03

Market Cap

5.8B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
TKC
GRFS
Founded
1993
1940
Country
Turkey
Spain
Employees
N/A
25247
Industry
Telecommunications Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Telecommunications
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.2B
5.8B
IPO Year
2001
N/A

Fundamental Metrics

Financial Performance
Metric
TKC
GRFS
Price
$6.16
$8.03
Analyst Decision
Hold
Analyst Count
0
2
Target Price
N/A
$10.15
AVG Volume (30 Days)
1.1M
646.0K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
2.52%
1.74%
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$45.35
$5.33
Revenue Next Year
$30.18
$6.50
P/E Ratio
$26.98
$18.67
Revenue Growth
N/A
N/A
52 Week Low
$5.35
$6.19
52 Week High
$7.60
$11.14

Technical Indicators

Market Signals
Indicator
TKC
GRFS
Relative Strength Index (RSI) 36.16 30.37
Support Level $5.48 $7.64
Resistance Level $6.16 $9.11
Average True Range (ATR) 0.13 0.30
MACD -0.10 -0.11
Stochastic Oscillator 17.92 4.38

Price Performance

Historical Comparison
TKC
GRFS

About TKC Turkcell Iletisim Hizmetleri AS

Turkcell Iletisim Hizmetleri AS provides mobile telephone services in Turkey. The firm's services portfolio includes high-quality mobile and fixed voice, data, TV, and digital services over its network. The firm also operates in the Turkish Republic of Northern Cyprus, Belarus, the Netherlands, and Ukraine. It has three main reportable segments: Turkcell Turkiye, Turkcell International, and Techfin. The Turkcell Turkiye segment, which derives the majority of revenue, comprises mainly telecommunication and technology services activities.

About GRFS Grifols S.A.

Grifols SA one of is global specialty plasma therapeutics companies developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend and enhance the lives of individuals who suffer from chronic and acute, often life-threatening, conditions, including primary and secondary immunological deficiencies, Chronic Inflammatory Demyelinating Polyneuropathy, immune-mediated ITP. Products and services are used to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases and a range of other medical conditions. Majority of revenue is from USA.

Share on Social Networks: